S25_gr02
Online link to source site
News offline code
True news - The journalist who made the decision: S25_gr05
The CNN article from May 17, 2025, regarding the approval of the Novavax COVID-19 vaccine is consistent with available information and can be considered reliable. According to reports from other reputable sources, such as the Associated Press and The Washington Post, the U.S. Food and Drug Administration (FDA) has granted full approval to the Novavax vaccine, but with significant limitations on its use.- Scope of approval: The Novavax vaccine has been approved by the FDA for use in individuals aged 65 and older, as well as those aged 12 to 64 who have at least one condition that increases the risk of severe COVID-19, such as asthma, diabetes, or obesity. (Source: apnews.com)
- Reasons for the limitations: The FDA did not provide specific reasons for imposing these restrictions, but the decision aligns with the agency’s broader strategy focused on protecting the most vulnerable populations.
- Expert reactions: Some experts expressed concern that limiting access to the vaccine for healthy adults may hinder the protection of high-risk individuals by those around them.
